Storage and handling
Store at controlled room temperature 15-30 C (59-86 F). Avoid freezing.
Store at controlled room temperature 15-30 C (59-86 F). Avoid freezing.
Povidone-iodine
Antiseptic
Antiseptic skin preparation
Do not use
-if allergic to iodine
-in the eyes
For external use only
Ask a doctor before use if injuries are
-deep or puncture wounds
-serious burns
Stop use and ask a doctor if
-redness, irritation, swelling or pain persists or increases
-infection occurs
Avoid pooling beneath patient
Avoid excessive heat. Store at room temperature.
Keep out of reach of children
In case of accidental ingestion, seek professional assistance or consult a poison control center immediately.
Apply locally as needed.
citric acid, disodium phosphate, nonoxynol-9, sodium hydroxide, water
1 800 760-3236 (Mon to Fri 8:30 AM-5:00 PM EST)
Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride 0.9% (9 mg/mL) in Water for Injection containing no antimicrobial agent or other added substance. The pH is between 4.5 and 7.0. Its chloride and sodium ion concentrates are approximately 0.154 mEq of each per milliliter and its calculated osmolality is 0.308 milliosmols per mL.
Sodium chloride occurs as colorless cubic crystals or white crystalline powder and has a saline taste. Sodium Chloride is freely soluble in water. It is soluble in glycerin and slightly soluble in alcohol. The empirical formula for sodium chloride is NaCl, and the molecular weight is 58.44.
Sodium chloride comprises over 90% of the inorganic constituents of the blood serum. Sodium chloride in water dissociates to provide sodium (Na+) and chloride (Cl-) ions. These ions are normal constituents of the body fluids (principally extracellular) and are essential for maintaining electrolyte balance. The small volume of Fluid and amount of sodium chloride provided by Sodium Chloride Injection, USP, 0.9% when used only as a vehicle for parenteral injection of drugs, is unlikely to exert a significant effect on fluid and electrolyte balance except possibly in very small infants.
Sodium Chloride Injection is used to flush intravascular catheters or as a sterile, isotonic single dose vehicle, solvent, or diluent for substances to be administered intravenously, intramuscularly or sub-cutaneously and for other extemporaneously prepared single dose sterile solutions according to instructions of the manufacture of the drug to be administered.
Sodium Chloride must be used with caution in the presence of congestive heart failure, circulatory insufficiency, kidney dysfunction or hypoproteinemia. Excessive amounts of sodium chloride by any route may cause hypokalemia and acidosis.
Excessive amounts by parental routes may precipitate congestive heart failure and acute pulmonary edema, especially seen in patients with preexisting cardiovascular disease and those receiving corticos-teroids, corticotropin or other drugs that may give rise to sodium retention. For use in newborns, when a Sodium Chloride solution is required for preparation or diluting medications, or in flushing intravenous catheters, only preservative-free Sodium Chloride Injection, USP, 0.9% should be used.
Since Sodium Chloride Injection does not contain antimicrobial agents and is intended for single use, any unused amount must be discarded immediately following withdrawal of any portion of the contents of the vial or ampul. Do not open ampul until it is to be used.
Consult the manufactures instructions for choice of vehicle, appropriate dilution or volume for dissolving the drug to be injected, including the route and rate of injection.
Pregnancy Category C: Animal reproductive studies have not been conducted with Sodium Chloride Injection USP 0.9%. It is also not known whether Sodium Chloride Injection USP 0.9% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Chloride Injection USP 0.9% should be given to a pregnant woman only if clearly needed.
Reactions which may occur because of this solution, added drugs or the technique of reconstitution or administration include febrile response, local tenderness, abscess, tissue necrosis or infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate countermeasures, and if possible, retrieve and save the remainder of the unused vehicle for examination.
When used as a diluent, solvent or intravascular flushing solution, this parental preparation is unlikely to pose a threat of sodium chloride or fluid overload except possible in very small infants. In the event these should occur, reevaluate the patient and institute appropriate corrective measures.
Before Sodium Chloride Injection, USP, 0.9% is used as a vehicle for the administration of a drug, specific references should be checked for any possible incompatibility with sodium chloride. The volume of the preparation to be used for diluting or dissolving any drug for injection is dependent on the vehicle concentration, dose and route of administration as recommended by the manufacture.
Sodium Chloride Injection, USP, 0.9% is also indicated for use in flushing intravenous catheters. Prior to and after administration of the medication, the intravenous catheter should be flushed in its entirety with Sodium Chloride Injection, USP, 0.9%. Use in accord with any warnings or precautions appropriate to the medication being administered. Parental drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
INSTRUCTIONS FOR USE
To open ampuls, using gauze, place thumb and forefinger on color line, break at constriction.
5 mL ampuls packaged in box of 25 each (NDC-65282-1505-1)
10 mL ampuls packaged in box of 25 each (NDC-65282-1510-1)
Store at controlled room temperature 15-30 C (59-86 F). Avoid freezing.
Manufactured for:
Spectra Medical Devices, Inc. 260-F Fordham Road, Wilmington, MA 01887
By: KM. Pharm. Co., LTD.
SM1500 Rev. B 12/00
Sodium Chloride Inj USP 0.9% 5mL
APLICARE
POVIDONE-IODINE SOLUTION
ANTISEPTIC
STERILE Solution
Package label Display Panel
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 52380-0001-1 | ML - Milliliter | 52380-0001 | edd25a2a-aabd-433e-b5a8-ef9471c1b244 | 1 | 2012-07-24 |
| 52380-0001-3 | ML - Milliliter | 52380-0001 | 9f05eb45-3f8e-4fd9-814a-476eb917bf5c | 1 | 2021-11-09 |
| 52380-0001-5 | EA - Each | 52380-0001 | 9755da7f-19a8-4706-8c70-17752ffe4175 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| POVIDONE-IODINE | ACTIVE INGREDIENT | 85H0HZU99M | 1 | |
| SODIUM CHLORIDE | ACTIVE INGREDIENT | 451W47IQ8X | 1 | |
| IODINE | ACTIVE MOIETY | 9679TC07X4 | 1 | |
| SODIUM CATION | ACTIVE MOIETY | LYR4M0NH37 | 1 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 1 | |
| NONOXYNOL-9 | INACTIVE INGREDIENT | 48Q180SH9T | 1 | |
| SODIUM HYDROXIDE | INACTIVE INGREDIENT | 55X04QC32I | 1 | |
| SODIUM PHOSPHATE, DIBASIC | INACTIVE INGREDIENT | GR686LBA74 | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 51688-8507 | 51688-8507-2 |
| 52380-0001 | 52380-0001-3 |
| 65282-1505 | 65282-1505-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| POVIDONE-IODINE | 85H0HZU99M | ACTIM |
| CITRIC ACID MONOHYDRATE | 2968PHW8QP | IACT |
| SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | IACT |
| SODIUM HYDROXIDE | 55X04QC32I | IACT |
| NONOXYNOL-9 | 48Q180SH9T | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| WATER | 059QF0KO0R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 40 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRAMUSCULAR | 26 mg | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 40 mg | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 40 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | SOLUTION / OPHTHALMIC | 0.13 %w/w | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 2.98 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | SOLUTION / OPHTHALMIC | 0.13 %w/w | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / SUBCUTANEOUS | 1 %w/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAVENOUS | 78 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRAVENOUS | 396 mg | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 40 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | CLOTH / TOPICAL | NA | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 2.98 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | SOLUTION / OPHTHALMIC | 0.13 %w/w | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | CLOTH / TOPICAL | NA | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | CLOTH / TOPICAL | NA | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | SOLUTION / OPHTHALMIC | 0.13 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRAVENOUS | 396 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | SOLUTION / OPHTHALMIC | 0.13 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / SUBCUTANEOUS | 26 mg | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / INTRAVENOUS | 200 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAMUSCULAR | 78 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | SOLUTION / OPHTHALMIC | 0.13 %w/w | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / INTRAVENOUS | 200 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | CLOTH / TOPICAL | NA | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAVENOUS | 78 mg | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / SUBCUTANEOUS | 14 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | CLOTH / TOPICAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / SUBCUTANEOUS | 26 mg | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / INTRAMUSCULAR | 40 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / SUBCUTANEOUS | 1 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRAMUSCULAR | 26 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAMUSCULAR | 78 mg | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / INTRAMUSCULAR | 40 mg | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / SUBCUTANEOUS | 14 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | CLOTH / TOPICAL | NA |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A206171-001 | SODIUM CHLORIDE 0.9% | SODIUM CHLORIDE | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | |
| A206171-002 | SODIUM CHLORIDE 0.9% | SODIUM CHLORIDE | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 |
| Application-product | TE code |
|---|---|
| A206171-001 | AP |
| A206171-002 | AP |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A206171-001 | SODIUM CHLORIDE 0.9% | 9MG/ML | INJECTABLE / INJECTION | AP | 2017-07-21 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A206171-001 | SODIUM CHLORIDE 0.9% | 9MG/ML | INJECTABLE / INJECTION | AP | 2017-07-21 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A206171-001 | SODIUM CHLORIDE 0.9% | 9MG/ML | INJECTABLE / INJECTION | AP | 2017-07-21 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A206171-001 | SODIUM CHLORIDE 0.9% | 9MG/ML | INJECTABLE / INJECTION | AP | 2017-07-21 | 74a2ff9319b5… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A206171-001 | AP | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A206171-002 | AP | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A206171-001 | AP | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A206171-002 | AP | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A206171-001 | AP | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A206171-002 | AP | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A206171-001 | AP | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A206171-002 | AP | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A206171-001 | AP | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A206171-002 | AP | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A206171-001 | AP | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A206171-002 | AP | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A206171-001 | AP | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A206171-002 | AP | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A206171-001 | AP | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A206171-002 | AP | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A206171-001 | AP | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A206171-002 | AP | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A206171-001 | AP | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A206171-002 | AP | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A206171-001 | AP | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A206171-002 | AP | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A206171-001 | AP | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A206171-002 | AP | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A206171-001 | AP | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A206171-002 | AP | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A206171-001 | AP | 1 | d06236e962d9… |
| 2024-10-29 15:01 UTC | 2024-10 | A206171-002 | AP | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A206171-001 | AP | 1 | 79d66fd596c7… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A206171-002 | AP | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A206171-001 | AP | 1 | 301d65b070ca… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A206171-002 | AP | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A206171-001 | AP | 1 | 1e350fbaab3a… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A206171-002 | AP | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A206171-001 | AP | 1 | 8072bd15b7f6… |
| 2024-05-31 18:47 UTC | 2024-05 | A206171-002 | AP | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A206171-001 | AP | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A206171-001 | AP | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A206171-001 | AP | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A206171-001 | AP | 1 | 74a2ff9319b5… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Sodium Chloride | SODIUM CHLORIDE | Spectra Medical Deviecs, LLC | 7e316d21-d6ad-4976-bd90-268fd7e51361 | 2024-01-12 | Adverse reactions | 65282-1505-1 65282-1505 65282150501 |
Adverse event summaries are temporarily unavailable. Other product information remains available.